Key result
Bovine jugular vein valves linked to ~6.7-fold higher endocarditis risk compared to homografts.
Why the study?
Infective endocarditis after pulmonary valve replacements in congenital heart disease is a significant concern, motivating an analysis of specific long-term risk factors after percutaneous or surgical replacement.
Does the type of valve and mode of deployment (percutaneous vs surgical, specifically bovine jugular vein valves like Melody and Contegra) increase the long-term risk of infective endocarditis compared to homografts in patients with congenital heart disease undergoing pulmonary valve replacement?
Cohort (n=1,170)
Yes
Does the type of valve and mode of deployment (percutaneous vs surgical, specifically bovine jugular vein valves like Melody and Contegra) increase the long-term risk of infective endocarditis compared to homografts in patients with congenital heart disease undergoing pulmonary valve replacement?
Answers are grounded in this paper and cite their sources.
Bovine jugular vein valves (both percutaneous Melody and surgical Contegra) carry a 5- to 6-fold higher risk of infective endocarditis than homografts regardless of deployment mode, whereas non-Contegra heterografts and Edwards Sapien valves do not significantly increase IE risk.
Background Infective endocarditis (IE) after pulmonary valve replacements in congenital heart disease is a significant concern. This study aimed to identify specific long‐term risk factors for IE after percutaneous pulmonary valve implantation or surgical pulmonary valve replacement. Methods and Results All patients with congenital heart disease from the National Register for Congenital Heart Defects with at least 1 pulmonary valve replacement before January 2018 were included. A total of 1170 patients (56.3% men, median age at study inclusion 12 [interquartile range {Q1–Q3} 5–20 years]) received 1598 pulmonary valve replacements. IE occurred in 4.8% of patients during a follow‐up of total 9397 patient‐years (median 10 [Q1–Q3, 6–10] years per patient). After homograft implantation 7 of 558 (1.3%) patients developed IE, after heterograft implantation 31 of 723 (4.3%) patients, and after Melody valve implantation 18 of 241 (7.5%) patients. Edwards Sapien and mechanical valves were used less frequently and remained without IE. The incidence of IE in heterografts excluding Contegra valves was 7 of 278 (2.5%), whereas the incidence of IE in Contegra valves was 24 of 445 (5.4%). The risk of IE was not increased compared with homografts if Contegra valves were excluded from the heterografts (hazard ratio [HR], 2.60; P =0.075). The risk of IE was increased for bovine jugular vein valves, Contegra valves (HR, 6.72; P <0.001), and Melody valves (HR, 5.49; P <0.001), but did not differ between Melody valves and Contegra valves (HR, 1.01; P =0.978). Conclusions Bovine jugular vein valves have the highest risk of IE, irrespective of the mode of deployment, either surgical or percutaneous.
No takes yet. Share an insight, caveat, or question.
Stammnitz et al. (2022) conducted a cohort in Congenital heart disease with pulmonary valve replacement (n=1,170). Contegra bovine jugular vein valve replacement vs. Surgical homograft pulmonary valve replacement was evaluated on Right ventricle-to-pulmonary artery conduit-related infective endocarditis (HR 6.72, 95% CI 2.80-16.16, p=<0.001). Bovine jugular vein valves increased infective endocarditis risk compared to homografts, both for surgical Contegra and percutaneous Melody valves.
Synapse has enriched 10 related papers. Consider them for comparative context: